<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Elan Corp. plc</title>
	<atom:link href="http://www.stockbloghub.com/tag/elan-corp-plc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ELN) Elan Redesigns Johnson &amp; Johnson Deal to Satisfy Biogen</title>
		<link>http://www.stockbloghub.com/2009/09/16/eln-elan-redesigns-johnson-johnson-deal-to-satisfy-biogen/15263</link>
		<comments>http://www.stockbloghub.com/2009/09/16/eln-elan-redesigns-johnson-johnson-deal-to-satisfy-biogen/15263#comments</comments>
		<pubDate>Wed, 16 Sep 2009 17:04:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15263</guid>
		<description><![CDATA[We believe the dispute between Elan Corp. (ELN) and its US partner Biogen Idec (BIIB) over multiple-sclerosis drug Tysabri has been resolved at last. The row started when Elan signed a deal with Johnson &#38; Johnson (JNJ) last July. But now, the two companies have amended this deal to drop the terms involving Tysabri. J&#38;J will now pay $885 million, down from the previously announced $1 billion for an 18.4% stake in Elan. However, J&#38;J’s $500 million investment for a majority stake in the Alzheimer&#8217;s disease pipeline remains unchanged. Although Elan claimed that the new terms will restore its &#8216;unintended breach&#8217; of contract with Biogen Idec related to Tysabri rights, we are yet to know whether its US partner has accepted this argument. Biogen and Elan have a 50-50 partnership ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/eln-elan-redesigns-johnson-johnson-deal-to-satisfy-biogen/15263/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Court Rules in Favor of Biogen Idec</title>
		<link>http://www.stockbloghub.com/2009/09/04/biib-court-rules-in-favor-of-biogen-idec/14470</link>
		<comments>http://www.stockbloghub.com/2009/09/04/biib-court-rules-in-favor-of-biogen-idec/14470#comments</comments>
		<pubDate>Fri, 04 Sep 2009 23:00:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14470</guid>
		<description><![CDATA[Biogen Idec (BIIB) received good news yesterday in the form of a favorable court ruling in its dispute with partner Elan Corp. PLC (ELN) regarding their 10-year collaboration for multiple sclerosis drug Tysabri. As a reminder, Elan took Biogen to court in early August 2009 in order to prevent Biogen from gaining control over Tysabri. Soon after, Johnson &#38; Johnson (JNJ) signed an agreement to acquire an 18.4% stake in Elan for $1.5 billion, Biogen claimed that Elan has breached the collaboration agreement between the two companies for Tysabri. In addition to its 18.4% stake in Elan and a majority stake in Elan’s Alzheimer&#8217;s disease pipeline, J&#38;J reportedly received an option to acquire Elan’s 50% stake in Tysabri, if there is a change in ownership at Biogen. Yesterday’s ruling found ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/biib-court-rules-in-favor-of-biogen-idec/14470/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharmaceuticals &amp; Biotech &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072</link>
		<comments>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072#comments</comments>
		<pubDate>Tue, 09 Jun 2009 18:48:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8072</guid>
		<description><![CDATA[The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x Incorporatedluding: Pfizer (PFE), 7.5x, Eli Lilly (LLY), 8.1x, Merck (MRK), 8.3x, Sanofi (SNY), 7.5x, AstraZeneca (AZN), 7.6x and GlaxoSmithKline (GSK), 9.3x based on our fiscal 2009 estimates. Attractive valuations, along with big dividend yields, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharmaceuticals &amp; Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043</link>
		<comments>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043#comments</comments>
		<pubDate>Mon, 08 Jun 2009 22:05:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8043</guid>
		<description><![CDATA[The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x Incorporatedluding: Pfizer (PFE), 7.5x, Eli Lilly (LLY), 8.1x, Merck (MRK), 8.3x, Sanofi (SNY), 7.5x, AstraZeneca (AZN), 7.6x and GlaxoSmithKline (GSK), 9.3x based on our fiscal 2009 estimates. Attractive valuations, along with big dividend yields, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

